ALOPM — Oncodesign Precision Medicine Opm SA Balance Sheet
0.000.00%
Last trade - 00:00- €6.90m
- €5.11m
- €1.07m
Annual balance sheet for Oncodesign Precision Medicine Opm SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|
| Period Length: | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | ARS | ARS |
| Standards: | FAS | FAS | FAS | FAS |
| Status: | Final | Final | Final | Final |
| Cash | ||||
| Short Term Investments | ||||
| Cash and Short Term Investments | 8.43 | 4.92 | 13.4 | 10.3 |
| Net Total Accounts Receivable | ||||
| Net Total Receivables | 2.59 | 1.55 | 2.89 | 3.74 |
| Prepaid Expenses | ||||
| Total Other Current Assets | ||||
| Total Current Assets | 11.2 | 6.54 | 16.4 | 14.4 |
| Gross Property, Plant And Equipment | ||||
| Accumulated Depreciation | ||||
| Net Property, Plant And Equipment | 0.156 | 0.932 | 0.896 | 0.76 |
| Net Intangible Assets | ||||
| Long Term Investments | ||||
| Other Long Term Assets | ||||
| Total Assets | 12.4 | 8.37 | 18.4 | 16.6 |
| Accounts Payable | ||||
| Accrued Expenses | ||||
| Notes Payable / Short Term Debt | ||||
| Current Portion of Long Term Debt / Capital Leases | ||||
| Total Other Current Liabilities | ||||
| Total Current Liabilities | 2.81 | 2.03 | 4.55 | 5.68 |
| Long Term Debt | ||||
| Total Long Term Debt | ||||
| Total Debt | ||||
| Total Other Liabilities | ||||
| Total Liabilities | 5.44 | 4.17 | 6.59 | 12.9 |
| Common Stock | ||||
| Additional Paid In Capital | ||||
| Retained Earnings (Accumulated Deficit) | ||||
| Other Equity | ||||
| Total Equity | 6.97 | 4.2 | 11.8 | 3.69 |
| Total Liabilities & Shareholders' Equity | 12.4 | 8.37 | 18.4 | 16.6 |
| Total Common Shares Outstanding |